Dr. Rahul Tyagi
About Dr. Rahul Tyagi
Dr. Rahul Tyagi is a Pharmacovigilance Scientist at Procter & Gamble with extensive experience in regulatory affairs and product stewardship in the cosmetics, drugs, and medical device sectors in India.
Title
Dr. Rahul Tyagi serves as a Pharmacovigilance Scientist at Procter & Gamble, a position he has held since 2021.
Work Experience at Procter & Gamble
Dr. Tyagi joined Procter & Gamble in 2014 as a Senior Researcher in Global Product Stewardship and was based in Mumbai Area, India. He transitioned to the role of Associate Scientist in 2017 and further progressed to become a Scientist by 2018. From 2018 to 2020, he worked on global product stewardship initiatives from Mumbai, Maharashtra, India. As of 2021, he holds the title of Pharmacovigilance Scientist at the company's United Kingdom office.
Previous Professional Roles
Before joining Procter & Gamble, Dr. Tyagi gained regulatory experience at various companies. From 2013 to 2014, he worked as a Regulatory Affairs Associate at Oriflame in New Delhi Area, India. Previously, he held positions at Apothecaries Private Limited, starting as a Clinical Research Executive from 2011 to 2012 and then as a Regulatory Executive from 2012 to 2013, also in New Delhi Area, India.
Education and Expertise
Dr. Tyagi graduated with a Bachelor of Physiotherapy (BPT) from B.C.I.P Kalka Ji in 2010. Furthermore, he completed a PG Diploma in Management from ICFAI University Tripura. His expertise encompasses end-to-end regulatory support for the cosmetics, drugs, and medical device sectors in India, and he has a comprehensive understanding of human physiology, pathology, neurology, general surgery, and orthopedics.
Regulatory and Managerial Experience
Dr. Tyagi has demonstrated proficiency in handling complex regulatory challenges, including executing product recalls. He holds expert knowledge in ICH-GCP, ICH-GMP, Schedule-M, and the Drugs & Cosmetics Act and Rules. His experience includes influencing activities at the highest FDA levels and resolving technical queries from the FDA. Additionally, he has hands-on experience in data review for CDSCO submissions, including clinical and non-clinical data, drug master files, and site master files as per Indian norms and ICH-CTD format.